GAABRYDA

Serial Number 90232607
Registration 7231187
700

Registration Progress

Application Filed
Oct 2, 2020
Under Examination
Jun 8, 2021
Approved for Publication
Apr 13, 2021
Published for Opposition
Apr 13, 2021
Registered
Nov 28, 2023

Trademark Image

GAABRYDA

Basic Information

Serial Number
90232607
Registration Number
7231187
Filing Date
October 2, 2020
Registration Date
November 28, 2023
Published for Opposition
April 13, 2021
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Nov 28, 2023
Registration
Registered
Classes
005

Rights Holder

Marinus Pharmaceuticals, Inc.

03
Address
100 Matsonford Road
5 Radnor Corporate Center, Suite 500
Radnor, PA 19087

Ownership History

Marinus Pharmaceuticals, Inc.

Original Applicant
03
Radnor, PA

Marinus Pharmaceuticals, Inc.

Owner at Publication
03
Radnor, PA

Marinus Pharmaceuticals, Inc.

Original Registrant
03
Radnor, PA

Legal Representation

Attorney
Keith Barritt

USPTO Deadlines

Next Deadline
1481 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-11-28)
Due Date
November 28, 2029
Grace Period Ends
May 28, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

32 events
Date Code Type Description Documents
Nov 28, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Nov 28, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Oct 27, 2023 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Oct 26, 2023 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Oct 12, 2023 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Oct 10, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Sep 28, 2023 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Sep 28, 2023 IUAF S USE AMENDMENT FILED Loading...
Jun 2, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 31, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 31, 2023 EXT4 S SOU EXTENSION 4 FILED Loading...
May 31, 2023 EX4G S SOU EXTENSION 4 GRANTED Loading...
Nov 10, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 8, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 8, 2022 EXT3 S SOU EXTENSION 3 FILED Loading...
Nov 8, 2022 EX3G S SOU EXTENSION 3 GRANTED Loading...
Mar 30, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 28, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 28, 2022 EXT2 S SOU EXTENSION 2 FILED Loading...
Mar 28, 2022 EX2G S SOU EXTENSION 2 GRANTED Loading...
Dec 7, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 3, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 3, 2021 EXT1 S SOU EXTENSION 1 FILED Loading...
Dec 3, 2021 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jun 8, 2021 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 13, 2021 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 13, 2021 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 24, 2021 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 10, 2021 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 27, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 17, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 6, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of seizures and epilepsy, status epilepticus, encephalopathies, neurodegenerative disease, cerebrovascular disease, movement disorders, traumatic brain injury and other neurologic conditions, substance abuse, substance withdrawal, dementia, delirium, schizophrenia, bipolar disorder, psychosis, depression, and other psychiatric conditions
First Use Anywhere: Sep 15, 2023
First Use in Commerce: Sep 15, 2023

Classification

International Classes
005